sorafenib increases 18-fdg colic uptake demonstration in patients with differentiated thyroid cancer索拉非尼增加18-fdg绞痛吸收示范分化型甲状腺癌患者.pdf

Ciappuccini et al. EJNMMI Research 2012, 2:18 /content/2/1/18 SHORT COMMUNICATION Open Access Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer 1* 2 3 4 Renaud Ciappuccini , Géraldine Trzepla , Natacha Heutte , Emmanuel Sevin , Marie Pierre Galais4 and Stéphane Bardet1 Abstract Background: To assess 18-fluorodeoxyglucose (FDG) bowel uptake in patients with differentiated thyroid cancer (DTC) treated with sorafenib. Findings: Visual (5-point scale) and high maximum standard uptake value (SUVmax) semi-quantitative analyses were conducted in 63 positron emission tomography (PET) studies performed in patients on sorafenib (group 1, n = 20), in a control group (group 2, n = 28) and in patients on sunitinib or vandetanib (group 3, n = 15). Moderate or high and diffuse bowel uptake (grade 4 or 5) was observed in 90% of the PET scans of group 1 versus none in group 2. Only 20% of PET scans in group 3 were scored grade 4. SUVmax values were significantly higher for all colic segments in group 1 than in group 2 (P 0.0001) or 3 (P 0.0004). This uptake pattern appeared rapidly (one month) and disappeared after sorafenib withdrawal. Conclusions: FDG uptake is increased in the colon of DTC patients treated by sorafenib. Keywords: Sorafenib, FDG PET, Thyroid cancer, Colic uptake Findings patients treated by other TKI such as sunitinib and Background vandetanib. Sorafenib is a new targeted therapy with an angiogenesis inhibiting activity, belonging to the tyrosine kinase inhi- Methods bitors (TKI) family [1]. This multikinase inhibi